Pharmaceutical

AbbVie acquires Cerevel Therapeutics for $8.7bn

AbbVie has completed its acquisition of all outstanding shares of Cerevel Therapeutics in a deal valued at $8.7bn.

Aug 3, 2024 - 04:00
AbbVie acquires Cerevel Therapeutics for $8.7bn
AbbVie has completed its acquisition of all outstanding shares of Cerevel Therapeutics in a deal valued at $8.7bn.
Read the original article

Tags:

Previous Article

Merck buys Mirus Bio to boost viral vector bioprocessing capacity

Next Article

AAIC 2024: Eisai presents positive long-term data with Leqembi

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: Biogen to slash 1,000 more jobs; key House panel proposes lowering Medicare out-of-pocket drug costs

STAT+: Pharmalittle: Biogen to slash 1,000 more jobs; k...

Jul 26, 2023

STAT+: Pharmalittle: FDA OKs new kind of drug to treat hot flashes; Alzheimer’s drug could cost Medicare up to $5 billion a year

STAT+: Pharmalittle: FDA OKs new kind of drug to treat ...

May 15, 2023

CDC recommends RSV monoclonal antibody for infants, high-risk young children

CDC recommends RSV monoclonal antibody for infants, hig...

Aug 3, 2023